The abstract titled "Sustained Anti-Thrombotic Efficacy Of CS585, A Novel Prostacyclin Receptor Agonist, Demonstrates Therapeutic Potential", was authored by L. Stanger, M Flores, P Yalavarthi and M. Holinstat, at University of Michigan, Ann Arbor, USA; and B. Dahlöf, Cereno Scientific, Gothenburg, Sweden.

The abstract will be presented by Livia Stanger, Graduate student at the Holinstat Lab at University of Michigan, led by Dr. Michael Holinstat, Professor in the Department of Pharmacology, the Department of Internal Medicine (Division of Cardiovascular Medicine), and the Department of Vascular Surgery at the University of Michigan. Dr. Holinstat leads Cereno's development programs at the University of Michigan and is Director of Translational Research at Cereno.

We are also very happy to announce that Dr. Michael Holinstat has been invited to introduce the session where the CS585 abstract is presented, with a presentation titled "New Mechanisms For Antiplatelet Therapies".

Presentation Date: Saturday, 16 November, 15:15-16:30 CST

Part of Session: Translational Discovery in Thrombosis and Anti-thrombotic Therapeutics

The abstract will be available here on Monday, November 11, 2024 at 04:00am CDT. (https://eppro01.ativ.me/web/planner.php?id=AHA24)

About AHA

AHA (American Heart Association) Scientific Sessions is open to scientists, clinicians, researchers, and healthcare professionals from all over the world. It provides a platform to discuss cutting-edge topics, including electrophysiology innovations, cardiology in athletes, and groundbreaking first-in-human therapeutics. The scientific sessions will cover the latest developments in cardiovascular health, scientific and clinical discussions, and other topics aimed at fostering innovation and participation from attendees.

About CS585

Drug candidate CS585 is an oral, highly potent, and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.

A license agreement for drug candidate CS585 with the University of Michigan provides Cereno exclusive rights to further development and commercialization of CS585.

In early November 2023, CS585 was highlighted bytop-tier medical journal Blood (https://ashpublications.org/blood/article-abstract/142/18/1556/497636/The-oxylipin-analog-CS585-prevents-platelet?redirectedFrom=fulltext)as a promising novel anti-thrombotic strategy without risk of bleeding.

New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 was presented at ESC Congress 2024, indicating that CS585 inhibits platelet activation and clot formation up to 24 hours post-administration.

For further information, please contact:

Henrik Westdahl, Director IR & Communications

Email:henrik.westdahl@cerenoscientific.com

Phone: +46 70-817 59 96

Sten R. Sörensen, CEO

Email:sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific develops innovative treatments for rare and common cardiovascular disease. The lead drug candidate, CS1, is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties. A Phase IIa trial evaluating CS1's safety, tolerability, and exploratory efficacy in patients with the rare disease pulmonary arterial hypertension (PAH) demonstrated that CS1 was safe, well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. CS1 study data, together with preclinical information, is consistent with reversing pathological remodeling. A collaboration agreement with global healthcare company Abbott allowed Cereno to use their cutting-edge technology CardioMEMS HF System in the trial. Since January 2024, we are delighted that the FDA's Expanded Access Program will enable patients with PAH, a serious life-threatening disease condition, to gain access to CS1 where no comparable alternative therapy options are available. Cereno's pipeline comprises two additional programs in development through research collaborations with the University of Michigan. CS014 is a new chemical entity with a multi-fold mechanism of action as an epigenetic modulator - regulating platelet activity, fibrinolysis, and clot stability for the prevention of thrombosis without an increased risk of bleeding as documented in preclinical trials. The drug candidate has also demonstrated a favorable profile in preclinical models of other cardiovascular diseases, such as PAH, with reverse remodeling of pulmonary arterial vessels and effects on vascular fibrosis. On 28th of June, 2024, Cereno initiated a first-in-human Phase I trial of CS014. Preclinical candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding. CS585 was in-licensed from the University of Michigan in 2023. The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. Based in Kendall Square, Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B).The Certified Adviser is Carnegie Investment Bank AB, certifiedadviser@carnegie.se.More information is on www.cerenoscientific.com.